Contents
13 February 2019
Vol 11, Issue 479
Vol 11, Issue 479
Focus
- Biology, biography, and the translational gap
Medicine-based evidence integrates biology and biography to help eliminate the translational gap between research and the clinic.
Research Articles
- Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models
Human platelet decoys prevented thrombosis in rabbits and inhibited cancer cell aggregation and extravasation in vitro and in a mouse model.
- DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment
Cellular and computational models and bronchial biopsies from asthma patients show that a DP2 antagonist reduces airway smooth muscle mass in asthma.
- Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer
PD-L1+ tumor cells, but not macrophages, are likely responsible for inhibiting tumor-specific T cells in early-stage human lung tumors.
- IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response
Mutant IDH1 coexpressed with inactivating TP53 and ATRX mutations in glioma enhances DNA repair, causing resistance to genotoxic therapies.
Editors' Choice
- A killer sidekick for antitumor T cells
Engineered NK cells kill myeloid-derived suppressor cells to aid CAR-T cell antitumor responses.
- One step solution for fighting bacteria and growing bone
The delivery of copper ions from collagen-bioactive glass composite scaffolds offers a promising one-step approach to treating bone infections while also promoting new bone and blood vessel formation.
Erratum
About The Cover
ONLINE COVER Platelets in Disguise. Platelet hyperactivation plays a principal role in thrombotic events and contributes to formation of tumor metastases. Current drugs that prevent platelet activation are associated with an increased risk of adverse events due to the long time required to reverse the drugs' effects. Rapidly reversible platelet inhibitors called platelet decoys (pictured here) have been developed by modifying human platelets (Papa et al.). Although platelet decoys cannot become activated, they still retain their ability to bind to other cell types. Platelet decoys showed antithrombotic effects in rabbits and reduced tumor metastases in mice. The antiplatelet effect was rapidly reversed by administration of normal human platelets. [CREDIT: PAPA ET AL./SCIENCE TRANSLATIONAL MEDICINE]